Brief: Teva And Celltrion Healthcare Announce Launch Of TRUXIMA Injection
May 4 (Reuters) - Celltrion HealthCare Co Ltd 091990.KQ :
* TEVA AND CELLTRION HEALTHCARE ANNOUNCE LAUNCH OF TRUXIMA®
(RITUXIMAB-ABBS) INJECTION FOR RHEUMATOID ARTHRITIS, ONLY
BIOSIMILAR TO RITUXAN® (RITUXIMAB) AVAILABLE IN UNITED STATES
FOR THIS INDICATION
* TEVA PHARMACEUTICAL INDUSTRIES LTD - TRUXIMA IS NOW
AVAILABLE
FOR TREATMENT OF GRANULOMATOSIS WITH POLYANGIITIS AND
MICROSCOPIC POLYANGIITIS
Source text for Eikon: ID:nBw8tjrgLa
Further company coverage: 091990.KQ
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Celltrion Healthcare Co
See all newsBrief: Celltrion USA says Ventegra Will Place FDA-Approved Biosimilar To Avastin , Vegzelma On Its Commercial Formulary As A Preferred Brand
Brief: Celltrion Healthcare To Acquire 92.7 Billion Won Worth Of Own Shares
Brief: Celltrion Healthcare Q3 Operating Profit 50.5 Billion Won, Down 30.4% From Year Earlier
Brief: Celltrion Usa- Announces Distribution And Incorporation Of Yuflyma (Adalimumab-Aaty) To Carepartners Specialty Pharmacy Cost Savings Programs
Brief: Celltrion Healthcare's Merger With Celltrion Approved In Shareholder Meeting -Yonhap